Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
2011 1
2013 2
2014 3
2015 4
2016 2
2017 1
2018 2
2019 1
2020 1
2023 1
2024 1
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Antiviral Treatment and Risk of Hearing Loss in Asymptomatic and Mild Symptomatic Infants With Congenital Cytomegalovirus.
Villaverde S, Pedrero-Tomé R, Papaevangelou V, Syridou G, Karagiannidou S, Lyall H, Payne H, Frick MA, Soler-Palacín P, Baquero-Artigao F, Rodríguez-Molino P, Fortuny-Guasch C, Rios-Barnés M, Sánchez-Mateos M, Saavedra-Lozano J, Bringué X, Moliner E, Castells L, Muga O, Vives-Oños I, Gkentzi D, Lombardi G, Tagarro A, Colino E, Couceiro JA, Rojo P, de Vergas J, Blázquez-Gamero D; cCMVnet Registry Study Group. Villaverde S, et al. Pediatr Infect Dis J. 2025 Mar 1;44(3):239-245. doi: 10.1097/INF.0000000000004583. Epub 2024 Oct 9. Pediatr Infect Dis J. 2025. PMID: 39383383
A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis.
Dierig A, Hoelscher M, Schultz S, Hoffmann L, Jarchow-MacDonald A, Svensson EM, Te Brake L, Aarnoutse R, Boeree M, McHugh TD, Wildner LM, Gong X, Phillips P, Minja LT, Ntinginya N, Mpagama S, Liyoyo A, Wallis RS, Sebe M, Mhimbira FA, Mbeya B, Rassool M, Geiter L, Cho YL, Heinrich N. Dierig A, et al. Trials. 2023 Jun 6;24(1):382. doi: 10.1186/s13063-023-07354-5. Trials. 2023. PMID: 37280643 Free PMC article. Clinical Trial.
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial.
Heinrich N, Manyama C, Koele SE, Mpagama S, Mhimbira F, Sebe M, Wallis RS, Ntinginya N, Liyoyo A, Huglin B, Minja LT, Wagnerberger L, Stoycheva K, Zumba T, Noreña I, Peter DD, Makkan H, Sloan DJ, Brake LT, Schildkraut J, Aarnoutse RE, McHugh TD, Wildner L, Boeree M, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM; PanACEA consortium. Heinrich N, et al. Lancet Infect Dis. 2025 Jul 8:S1473-3099(25)00213-0. doi: 10.1016/S1473-3099(25)00213-0. Online ahead of print. Lancet Infect Dis. 2025. PMID: 40645196 Free article.
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial.
Minja LT, van der Feltz I, Manyama C, Mpagama S, Mhimbira F, Noreña I, Sebe M, Rassool M, Wallis RS, Ntinginya N, Liyoyo A, Mbeya B, Wagnerberger L, Zumba T, Peter DD, Makkan H, Sloan DJ, Brake LT, Schildkraut JA, Aarnoutse R, McHugh TD, Wildner L, Boeree MJ, Geiter L, Cho YL, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM, Heinrich N; PanACEA consortium. Minja LT, et al. Lancet Infect Dis. 2025 Jul 8:S1473-3099(25)00289-0. doi: 10.1016/S1473-3099(25)00289-0. Online ahead of print. Lancet Infect Dis. 2025. PMID: 40645198 Free article.
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB.
Koele SE, Stoycheva K, Mtweve C, Manyama C, Mpagama S, Mhimbira F, Wallis R, Ntinginya NE, Liyoyo A, Huglin B, Minja LT, Wagnerberger L, Zumba T, Noreña I, Peter DD, Beattie T, Makkan H, Sloan DJ, Te Brake L, Aarnoutse RE, McHugh TD, Wildner L, Schildkraut J, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM, Heinrich N; PanACEA consortium. Koele SE, et al. J Antimicrob Chemother. 2025 Aug 1;80(8):2305-2313. doi: 10.1093/jac/dkaf210. J Antimicrob Chemother. 2025. PMID: 40613338 Free PMC article. Clinical Trial.
22 results